COVID-19 patient treated with ProTrans
NextCell Pharma AB (“NextCell” or “the Company”) announces that the first patient with severe pneumonia, as a result of COVID-19 infection, has now been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase 1b study ProTrans19+SE is in progress led by Principal Investigator Associate Professor Josefin Sundh.
NextCell's drug candidate, ProTrans, is an immune- balancing cell therapy for the treatment of autoimmune diseases and inflammatory conditions. Patients with severe pneumonia as a result of by SARS-CoV-2 infection are at risk of rapid detioration, potentially leading to acute respiratory distress syndrome (ARDS) due to hyper-inflammation of the lungs.
ProTrans is given as a peripheral infusion with the aim of reducing this hyper-inflammation. The goal of the treatment is to shorten hospital stay and time for rehabilitation, and to save lives.
"The treatment was performed according to plan and the patient is doing well," says Josefin Sundh, Consultant at Department of Cardiology, Respiratory Medicine and Physiology, Örebro University Hospital and Associate Professor at the Department of Respiratory Medicine, Faculty of Medicine and Health, Örebro University.
The study, entitled “Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton’s Jelly - Umbilical Cord Mesenchymal Stromal Cells (ProTrans): Open Phase IB Clinical Trial” is sponsored by NextCell and will include 9 patients with severe pneumonia and confirmed COVID-19 (SARS-CoV-2) infection, who will be treated with low (3 patients), medium (3 patients), or high dose (3 patients) ProTrans.
NextCell will provide updates after the completion of each dose cohort, ie when all 3 patients in each dose group have received treatment. The study is registered on clinicaltrials.gov (NCT04896853). ProTrans is furthermore under evaluat for the treatment of severe pneumonia in COVID-19 infected patients in a Canadian phase 2 clinical trial with a total of 48 patients, ProTrans19+CA (NCT04869397).
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.
Tags: